You searched for "macular"

2476 results found

Vabysmo receives NICE approval

The National Institute for Health and Care Excellence (NICE) has recently approved Vabysmo▼(faricimab) for treating adults with visual impairment due to macular oedema secondary to branch and central retinal vein occlusion (BRVO and CRVO). The NICE approval of Vabysmo was...

CHEC Loughborough CPD Open Evening

This CPD session on 'Decoding Macular OCT: Mastering Membranes and Holes - Empowering Optometrists in Referral Decision-Making' will be hosted by Mahmoud Rabie, Consultant Ophthalmologist and Clinical Director of Ophthalmology at CHEC. Throughout the evening, you will be able to...

Practice patterns of uveal melanoma management with Iodine-125 brachytherapy

With the 2006 Collaborative Ocular Melanoma Study Group (COMS) study demonstrating no difference in survival outcomes for participants randomised to either iodine-125 brachytherapy or enucleation, the majority of primary uveal melanomas in the United States are now treated with brachytherapy....

Efficacy and safety of intravitreal faricimab in nAMD, DME and RVO

This paper is an analysis of data extracted from 13 eligible studies in the context of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), collected from systematic literature search of MEDLINE, Embase, and Cochrane...

Neighbourhood deprivation and risk of age-related eye diseases

In this large epidemiological study, the authors sought to determine if neighbourhood wealth affects age-related ocular health. In particular they wished to see if there was a correlation between social deprivation and macular degeneration, cataract, diabetes-related eye complications, and glaucoma....

Visual outcomes after surgery for primary rhegmatogenous retinal detachment in era of microincision vitrectomy

This is a prospective, multicentre, nationwide study between 2016 and 2017, to investigate the preoperative ocular factors, surgical techniques (pars plana vitrectomy (PPV) or scleral buckling (SB), or combined procedures) for rhegmatogenous retinal detachment (RRD) and postoperative best corrected visual...

Exploring the potential of neurodegenerative disease screening within age-related eye disease research

The authors recruited healthy controls aged between 60 and 75-years-old, previously enrolled into a registry as patients following cataract surgery without age-related macular degeneration (AMD). Exclusion criteria included dense cataract, retinal disease, ocular inflammatory disease, moderate glaucoma, optic neuropathy, cancer,...

Pioneering eye device restores reading vision to blind eyes

A pivotal European clinical trial of a new electronic eye implant has seen remarkable results. The study, published in the New England Journal of Medicine, showed 84% of participants were able to read letters, numbers and words using prosthetic vision...

Deciphering dark retinal patches

We present a case of bilateral extensive dark without pressure (DWP) located outside the retinal vascular arcades in a young female. This retinal finding is benign but, in some instances, darkened retinal patches could be associated with potential sight-threatening conditions....

Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders

Medical records of 15 paediatric patients (onset before age of 16) affected by refractory non-infectious uveitis (NIU) and treated by tocilizumab (TCZ) were reviewed. Data were extracted from the international AIDA Network for uveitis registry and Behcet’s disease registries. They...

The management of chronic uveitis

A 40-year-old company executive is referred from another unit with recurrent anterior and posterior uveitis for 12 months and the inflammatory markers are raised. Review of systems This is a case of chronic uveitis which needs a thorough workup and...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...